Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50J. Clin. Oncol 2021 Apr 19;[EPub Ahead of Print], M Reck, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, M Gottfried, N Peled, A Tafreshi, S Cuffe, M O'Brien, S Rao, K Hotta, TA Leal, JW Riess, E Jensen, B Zhao, MC Pietanza, JR Brahmer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.